Trial Profile
A multicenter phase 2 randomized trial of single-agent ALIMTA [pemetrexed] or ALIMTA with sequentially administered GEMZAR [gemcitabine] as first-line chemotherapy in elderly patients or patients who are not eligible for platinum-based chemotherapy with advanced NSCLC [non-small cell lung cancer]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jun 2007
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 25 Jun 2007 New trial record.